Treatment of Relapsed Acute Myeloid Leukemia.
Thol F, Ganser A.
Curr Treat Options Oncol. 2020 Jun 29;21(8):66. doi: 10.1007/s11864-020-00765-5.
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I.
Int J Hematol. 2022 Jun;115(6):762-777. doi: 10.1007/s12185-022-03353-5. Epub 2022 May 9.
A review of treatment options employed in relapsed/refractory AML.
Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, Dharmaratna D, Dandwani M, Moin K.
Hematology. 2023 Dec;28(1):2196482. doi: 10.1080/16078454.2023.2196482.
Cytogenetic patterns of relapse following allogeneic stem cell transplantation in morphologic complete remission in patients with acute myeloid leukemia.
Rashidi A, Cashen AF.
Leuk Res. 2015 Jun;39(6):553-4. doi: 10.1016/j.leukres.2015.02.012. Epub 2015 Mar 20.
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M.
JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605.
Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Li R, Wang Z, Zhang Y, Guo M, Ni X, Chen J, Chen L, Gao L, Gong S, Tang G, Yang J, Wang J.
Ann Hematol. 2023 Jan;102(1):89-97. doi: 10.1007/s00277-022-05061-w. Epub 2022 Dec 21.
Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia.
Umeda M, Ma J, Huang BJ, Hagiwara K, Westover T, Abdelhamed S, Barajas JM, Thomas ME, Walsh MP, Song G, Tian L, Liu Y, Chen X, Kolekar P, Tran Q, Foy SG, Maciaszek JL, Kleist AB, Leonti AR, Ju B, Easton J, Wu H, Valentine V, Valentine MB, Liu YC, Ries RE, Smith JL, Parganas E, Iacobucci I, Hiltenbrand R, Miller J, Myers JR, Rampersaud E, Rahbarinia D, Rusch M, Wu G, Inaba H, Wang YC, Alonzo TA, Downing JR, Mullighan CG, Pounds S, Babu MM, Zhang J, Rubnitz JE, Meshinchi S, Ma X, Klco JM.
Blood Cancer Discov. 2022 May 5;3(3):194-207. doi: 10.1158/2643-3230.BCD-21-0160.
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N.
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study.
Klein K, Beverloo HB, Zimmermann M, Raimondi SC, von Neuhoff C, de Haas V, van Weelderen R, Cloos J, Abrahamsson J, Bertrand Y, Dworzak M, Fynn A, Gibson B, Ha SY, Harrison CJ, Hasle H, Elitzur S, Leverger G, Maschan A, Razzouk B, Reinhardt D, Rizzari C, Smisek P, Creutzig U, Kaspers GJL.
Pediatr Blood Cancer. 2022 Jan;69(1):e29341. doi: 10.1002/pbc.29341. Epub 2021 Sep 17.
Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics.
Zhou YL, Zhao MY, Gale RP, Jiang H, Jiang Q, Liu LX, Qin JY, Cao SB, Lou F, Xu LP, Zhang XH, Huang XJ, Ruan GR.
Leukemia. 2024 Jan;38(1):223-225. doi: 10.1038/s41375-023-02085-7. Epub 2023 Nov 22.
